New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:17 EDTINCYIncyte to present data from multiple cancer programs at ASCO meeting
Incyte will present new data from its lead cancer programs focused on onco-inflammation, immuno-oncology and myeloproliferative neoplasms at the 50th Annual Meeting of the American Society of Clinical Oncology from May 30 to June 3. Data to be presented include full results from RECAP, the Phase II trial of ruxolitinib in combination with capecitabine in metastatic pancreatic cancer. Topline results showed an overall survival benefit in a pre-specified subgroup analysis of patients. Also being presented are preliminary findings from a Phase I/II study of Incyte’s IDO1 inhibitor, INCB24360, in combination with ipilimumab in patients with metastatic melanoma, designed to examine potential synergy with other cancer immunotherapies. Full results will be presented from the pivotal Phase III RESPONSE trial of ruxolitinib in patients with uncontrolled polycythemia vera, the first Phase III study to evaluate a JAK inhibitor as a treatment for patients with PV, which met its primary endpoint.
News For INCY From The Last 14 Days
Check below for free stories on INCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
13:39 EDTINCYIncyte reported strong Q2 results, says Leerink
Subscribe for More Information
13:18 EDTINCYIncyte shares defended at UBS
Subscribe for More Information
12:52 EDTINCYIncyte weakness a buying opportunity, says Brean Capital
Subscribe for More Information
07:22 EDTINCYIncyte raises FY14 Jakafi net product revenue view to $330M-$340M
Subscribe for More Information
07:15 EDTINCYIncyte reports Q2 EPS (22c), may not compare to consensus (4c)
Reports Q2 revenue $99.6M, consensus $127.19M.
July 30, 2014
08:32 EDTINCYIncyte announces clinical trial agreement with Genentech
Subscribe for More Information
July 28, 2014
07:02 EDTINCYIncyte says FDA approves supplemental labeling for Jakafi
Subscribe for More Information
July 24, 2014
06:57 EDTINCYIncyte trial miss does not impact Jakafi assumptions, says Leerink
Subscribe for More Information
July 23, 2014
16:41 EDTINCYIncyte's Ruxolitinib shows no statistical significance in primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use